[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100498835":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":40,"responsibleParty":58,"collaborators":26,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":26,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":26,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":26,"overallStatus":43,"whyStopped":26,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"The First Affiliated Hospital with Nanjing Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A: radical chemoradiotherapy group;","SHAM_COMPARATOR","Concurrent chemotherapy (2 courses): Lipusu (T) + Cisplatin (DDP) scheme: T 135mg\u002Fm2 ivgtt, d1, 3week\\*2cycles; DDP 75mg\u002Fm2 ivgtt, d2, 3week\\*2cycles; Radiotherapy scheme: intensity modulated radiotherapy PTV50-54Gy, PGTV 56-60Gy, conventional fractionation.",[13],"Combination Product: Concurrent chemotherapy (2 courses)",{"label":15,"type":16,"description":17,"interventionNames":18},"Group B: radical chemoradiotherapy combined with consolidation chemotherapy group","EXPERIMENTAL","Consolidation chemotherapy (4 courses): After the concurrent chemoradiotherapy is over, after 2-3 weeks of rest, the patients in the consolidation chemotherapy group will be given 4 cycles of consolidation chemotherapy, and the chemotherapy regimen is the same as the concurrent chemotherapy regimen; Radiotherapy scheme: intensity modulated radiotherapy PTV50-54Gy, PGTV 56-60Gy, conventional fractionation.",[19],"Combination Product: Consolidation chemotherapy (4 courses)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"COMBINATION_PRODUCT","Consolidation chemotherapy (4 courses)","Consolidation chemotherapy (4 courses): After the concurrent chemoradiotherapy is over, after 2-3 weeks of rest, the patients in the consolidation chemotherapy group will be given 4 cycles of consolidation chemotherapy, and the chemotherapy regimen is the same as the concurrent chemotherapy regimen;",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Concurrent chemotherapy (2 courses)","Lipusu (T) + Cisplatin (DDP) program: T 135mg\u002Fm2 ivgtt, d1, 3week\\*2cycles; DDP 75mg\u002Fm2 ivgtt, d2, 3week\\*2cycles;",[9],[32],{"name":33,"affiliation":5,"role":34},"Xiaolin GE, MM","STUDY_DIRECTOR",[36],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","13951818797","doctorsxl@163.com",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"The First Affiliated Hospital of Nanjing Medical University","RECRUITING","Nanjing","Jiangsu","210009","China","CN",{"type":50,"coordinates":51},"Point",[52,53],118.77778,32.06167,{"lat":53,"lon":52},[56],{"name":57,"role":37,"phone":38,"phoneExt":26,"email":39},"Xiaolin Ge, PhD",{"type":59,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100498835","comparison-of-chemoradiotherapy-and-chemoradiotherapy-combined-with-consolidation-chemotherapy-for-escc-100498835",false,"NCT05775419","Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC","A Prospective Randomized Controlled Clinical Study Comparing Curative Effect of Non-surgical Esophageal Squamous Cell Carcinoma With Radical Chemoradiotherapy and Radical Chemoradiotherapy Combined With Consolidation Chemotherapy","Inclusion Criteria:\n\n1. Age 18-70 years old, not limited to male or female; at least able to take liquid diet;\n2. Esophageal squamous cell carcinoma proved by histopathology;\n3. Esophageal squamous cell carcinoma that is inoperable or refuses surgery,\n4. According to the 2017 8th edition of AJCC esophageal cancer new staging criteria, the tumor is T2N0M0-TxNxM0 stage;\n5. ECOG 0-1; life expectancy \\> 6 months;\n6. No chemotherapy was used before selection;\n7. No history of radiotherapy;\n8. No surgical treatment;\n9. No serious allergic history;\n10. Hemoglobin 100 g\u002FL, WBC3.5109\u002FL, neutrophils 1.5109, platelets 100109\u002FL; CR1.5 upper limit of normal, TB2.5 upper limit of normal, AST and ALT2.5 upper normal limit, AKP2.5 upper normal limit ; Be able to understand the research and have signed the informed consent;\n\nExclusion Criteria:\n\n1. History of malignant tumors in other parts;\n2. Duplicate carcinoma of the esophagus;\n3. Pregnant or lactating patients;\n4. Fertility but not using contraceptive measures;\n5. Serious comorbidities: very high-risk hypertension, severe pulmonary function impairment, massive myocardial infarction, cardiac function ≥ grade II, mental history and severe diabetes;\n6. During the active period of infectious diseases;\n7. Participate in other clinical trials at present or within four weeks before enrollment;\n8. Simultaneous treatment with other anti-cancer drugs (including anti-cancer traditional Chinese medicine);\n9. After esophageal stent placement;\n10. Cases with perforation tendency;\n11. Have a history of organ transplantation.\n12. Widespread metastases throughout the body, including lung, liver, bone, and intracranial metastases;\n13. Known or suspected allergic to chemotherapy drugs; According to the judgment of the investigator, there are concomitant diseases that seriously endanger the patient's safety or affect the patient's completion of the study.","ALL","18 Years","70 Years",{"count":71,"type":72},1216,"ESTIMATED","INTERVENTIONAL",[75],"NA","This study is a phase III, multicenter, prospective randomized controlled clinical study comparing the efficacy of non-surgical esophageal squamous cell carcinoma with radical chemoradiotherapy and radical chemoradiotherapy combined with consolidation chemotherapy. The survival time and side effects of patients were observed and compared.",[78,79,80],"Esophageal Squamous Cell Carcinoma","Chemotherapy Effect","Side Effect of Drug","2023-03-16",{"date":83,"type":84},"2023-03-20","ACTUAL",{"date":86,"type":84},"2021-06-30",{"date":88,"type":72},"2028-06-30",{"name":5,"class":6},1]